BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND ECT2L, 345930, C6orf91, Q008S8, LFDH, dJ509I19_3, dJ509I19_2, ENSG00000203734 AND Clinical Outcome
1477 results:

  • 1. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
    Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
    Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study.
    Wagner T; Toft BG; Lauritsen J; Bandak M; Christensen IJ; Engvad B; Kreiberg M; Agerbæk M; Dysager L; Carus A; Rosenvilde JJ; Berney D; Daugaard G
    Eur J Cancer; 2024 May; 202():114025. PubMed ID: 38531266
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
    Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
    Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Neurosurgical treatment of tumors of the pineal region - literature review and overview of cases at OMIII].
    Mezei T; Báskay J; Pollner P; Kovács V; Markia B; Nagy G; Bajcsay A; Sipos L
    Magy Onkol; 2024 Mar; 68(1):27-35. PubMed ID: 38484373
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial.
    Alves Costa Silva C; Piccinno G; Suissa D; Bourgin M; Schreibelt G; Durand S; Birebent R; Fidelle M; Sow C; Aprahamian F; Manghi P; Punčochář M; Asnicar F; Pinto F; Armanini F; Terrisse S; Routy B; Drubay D; Eggermont AMM; Kroemer G; Segata N; Zitvogel L; Derosa L; Bol KF; de Vries IJM
    Nat Commun; 2024 Feb; 15(1):1633. PubMed ID: 38395948
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
    Kim JY; Kim J; Kim YI; Yang DH; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
    Sci Rep; 2024 Feb; 14(1):4047. PubMed ID: 38374188
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. 5-Hydroxymethylcytosine Profiling of cell-Free DNA Identifies Bivalent Genes That Are Prognostic of Survival in High-Risk Neuroblastoma.
    Chennakesavalu M; Moore K; Chaves G; Veeravalli S; TerHaar R; Wu T; Lyu R; Chlenski A; He C; Piunti A; Applebaum MA
    JCO Precis Oncol; 2024 Jan; 8():e2300297. PubMed ID: 38295320
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. GammaTile
    Yekula A; Gessler DJ; Ferreira C; Shah R; Reynolds M; Dusenbery K; Chen CC
    J Neurooncol; 2024 Feb; 166(3):441-450. PubMed ID: 38281303
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection.
    Kameda-Smith MM; Ragulojan M; Elliott C; Bliss L; Moore H; Sader N; Alsuwaihel M; Tso MK; Dakson A; Ajani O; Yarascavitch B; Fleming A; Mehta V; Aminnejad M; Farrokhyar F; Singh SK;
    Childs Nerv Syst; 2024 May; 40(5):1339-1347. PubMed ID: 38279985
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Predictive and prognostic biomarkers in urological tumours.
    Cimadamore A; Franzese C; Di Loreto C; Blanca A; Lopez-Beltran A; Crestani A; Giannarini G; Tan PH; Carneiro BA; El-Deiry WS; Montironi R; Cheng L
    Pathology; 2024 Mar; 56(2):228-238. PubMed ID: 38199927
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The Application of Sodium Fluorescein in Resection of Medulloblastoma Under YELLOW 560 Filter: Feasibility and Preliminary Results of a Monocentric Cohort and Systematic Review.
    Falco J; Broggi M; Rubiu E; Schiariti M; Restelli F; Mazzapicchi E; La Corte E; Ferroli P; Acerbi F
    World Neurosurg; 2024 Mar; 183():e386-e394. PubMed ID: 38154682
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
    Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
    J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
    Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
    Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. PATIENT-RELATED FACTORS AND clinical MANAGEMENT outcomeS OF RETINOBLASTOMA IN CALABAR, NIGERIA.
    Nkanga ED; Nlemadim AC; Arazi M; Nkanga DG; Duke RE; Fabian ID; Nkanga ED; Odey FA; Meremikwu MM
    West Afr J Med; 2023 Dec; 40(12 Suppl 1):S36-S37. PubMed ID: 38070170
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
    Zhao S; Li Y; Xu J; Shen L
    Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
    Gambichler T; Iordanou M; Becker JC; Susok L
    Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. CD8+CD103+PD1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis.
    Romagnoli G; D'Alessandris QG; Capone I; Tavilla A; Canini I; Lapenta C; Buccarelli M; Giordano M; Tirelli V; Sanchez M; Fragale A; Giannetti S; Di Bonaventura R; Lauretti L; Biffoni M; Ricci-Vitiani L; Pallini R; Gabriele L
    Immunology; 2024 Feb; 171(2):198-211. PubMed ID: 37884280
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Independent prognostic biomarker FERMT3 associated with immune infiltration and immunotherapy response in glioma.
    Zhuo S; Tang C; Yang L; Chen Z; Chen T; Wang K; Yang K
    Ann Med; 2023; 55(2):2264325. PubMed ID: 37795794
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
    La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
    Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 74.